Melanotan II
Also known as: MT-II, MT-2, Barbie Drug
What Is Melanotan II?
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), originally developed by researchers at the University of Arizona in the 1990s as a potential photoprotective agent. The researchers hypothesized that inducing a “therapeutic tan” could protect against UV-induced skin cancers.
That original research goal was never realized. Instead, MT-II became one of the most widely used grey-market peptides globally, primarily for cosmetic tanning and secondarily for its sexual arousal effects. It is commonly called the “Barbie drug” on social media and is popular in fitness and bodybuilding subcultures.
MT-II is a nonselective melanocortin receptor agonist — it activates MC1R (skin pigmentation), MC3R and MC4R (sexual arousal, appetite suppression), and MC5R (sebaceous gland function). This nonselective activation is why MT-II produces both tanning and sexual side effects, and why it is pharmacologically distinct from afamelanotide (Melanotan I/Scenesse), which is an FDA-approved MC1R-selective agonist used to treat erythropoietic protoporphyria.
How It Works
MT-II stimulates melanogenesis by activating melanocortin 1 receptors (MC1R) on melanocytes, triggering the production of eumelanin — the dark pigment responsible for tanning. Unlike UV-induced tanning, which requires DNA damage to initiate the tanning cascade, MT-II activates melanocytes directly.
MC1R activation (skin): Promotes eumelanin synthesis and distribution, resulting in skin darkening. This occurs with or without UV exposure, though UV exposure amplifies the effect.
MC3R/MC4R activation (brain): MT-II crosses the blood-brain barrier. MC4R activation in the hypothalamus causes sexual arousal (the mechanism later isolated and developed into bremelanotide/Vyleesi, the FDA-approved female sexual dysfunction drug). MC4R activation also suppresses appetite.
MC5R activation (sebaceous glands): May increase sebum production. The clinical significance is unclear.
The nonselective nature of MT-II means users cannot get the tanning effect without also experiencing the neurological effects (nausea, appetite suppression, sexual arousal).
What the Research Actually Shows
The Clinical Data
MT-II has limited formal clinical data. The original University of Arizona research program produced early-phase studies before the molecule’s development was abandoned in favor of more selective derivatives.
Dorr RT et al. (Life Sci, 1996;58(20):1777–1784): Phase I study demonstrating dose-dependent tanning in human subjects following subcutaneous injection. Higher doses produced significant nausea and facial flushing. Confirmed pharmacological activity in humans.
Wessells H et al. (Urology, 2000;56(4):641–646): Study in 20 men with organic erectile dysfunction. Subcutaneous MT-II induced erections in 17 of 20 subjects, but nausea was a significant side effect, limiting its practical use for sexual dysfunction.
Levine N et al. (Arch Dermatol, 1991;127(3):357–362): One of the earliest studies confirming that synthetic α-MSH analogues could induce pigmentation in fair-skinned subjects without UV exposure.
Adverse Event Reports
The bulk of safety information about MT-II comes not from controlled trials but from case reports and post-marketing surveillance of unregulated use:
Melanoma association: At least five published case reports describe melanoma developing during or shortly after MT-II use (Hjuler KF et al., Dermatology, 2014). All patients had additional risk factors (fair skin, UV exposure, family history). A causal link has not been established — a 2021 review concluded the melanoma risk in MT-II users is likely attributable to their concurrent heavy UV exposure and sun-seeking behavior rather than the peptide itself. However, MT-II stimulates the very cells (melanocytes) from which melanoma arises, making theoretical concern reasonable.
Mole changes: Multiple reports of new nevi (moles) appearing, existing moles darkening or changing shape, and atypical melanocytic proliferation during MT-II use.
Rhabdomyolysis and renal dysfunction: A 39-year-old man who injected 6 mg (approximately 6x the typical starting dose) developed sympathomimetic toxicity, rhabdomyolysis (CPK peaked at 17,773 IU/L), and acute kidney injury requiring ICU admission.
Priapism: Multiple case reports of prolonged, painful erections requiring emergency department intervention.
Other reported effects: Nausea (nearly universal at effective doses), facial flushing, fatigue, decreased appetite, yawning, uneven pigmentation.
MT-II’s pharmacological activity (tanning, sexual arousal) is well-established from early clinical studies. However, the safety profile is derived primarily from uncontrolled self-administration reports rather than systematic clinical evaluation. The molecule was abandoned for clinical development specifically because its nonselective receptor profile produced too many unwanted effects. Evidence level: Limited Human.
Safety Profile
MT-II carries a unique safety concern profile among grey-market peptides:
Melanocyte stimulation and melanoma risk: MT-II activates the same cells from which melanoma originates. While no causal link between MT-II and melanoma has been definitively proven, the theoretical mechanism is biologically plausible — promoting melanocyte proliferation and activity in individuals who are also engaging in UV exposure (which most MT-II users do to amplify the tanning effect) creates a compounded risk scenario.
Nonselective receptor activation: MT-II cannot be used for tanning without also affecting appetite, sexual function, and potentially other neurological pathways. The FDA-approved derivative bremelanotide (Vyleesi) was specifically designed to isolate the MC4R sexual function effect from the MC1R tanning effect — evidence that the pharmaceutical industry considered MT-II’s nonselective profile unacceptable.
Uncontrolled pigmentation: MT-II can cause uneven darkening, darkening of moles and freckles, pigmentation of scars, and other cosmetically undesirable effects that may persist for months after discontinuation.
No established safe dose: Self-administration protocols circulating online have no basis in published clinical pharmacology.
Legal and Regulatory Status
FDA: Not approved for any indication. The FDA has issued public warnings against the use of MT-II products. Products sold as MT-II are considered unapproved new drugs.
Category 2: Listed among the peptides that cannot be legally compounded by 503A or 503B pharmacies.
WADA: Prohibited under S0 (Non-Approved Substances) as a non-approved pharmacological substance.
International: The UK’s MHRA, Australia’s TGA, and multiple European health agencies have issued specific warnings about MT-II. In Australia, it is a Schedule 4 (prescription-only) substance, and the TGA has imposed multi-million dollar penalties on companies marketing melanocortin analogues.
Grey-market availability: Widely available online in injectable and nasal spray formulations. Product quality is completely unverified. Analysis of online-purchased MT-II products has revealed significant variability in peptide content and purity.
Common Vendor Claims vs. Reality
| What vendors say | What the evidence shows |
|---|---|
| ”Safe, natural tan without UV” | MT-II produces tanning but is not safe — it is an unapproved drug with documented adverse events including rhabdomyolysis and priapism |
| ”Protects against skin cancer” | No evidence MT-II prevents skin cancer. Multiple case reports associate MT-II use with melanoma (though causality is unproven) |
| “No side effects at low doses” | Nausea is nearly universal at effective tanning doses. Facial flushing, appetite suppression, and sexual effects occur in most users |
| ”Same as Scenesse/afamelanotide” | False — Scenesse is a different molecule (linear, MC1R-selective, FDA-approved for erythropoietic protoporphyria). MT-II is a cyclic, nonselective agonist that was never approved for any indication |
| ”Used by millions safely” | Widespread use does not equal safety demonstration. Adverse events from unregulated use are likely underreported |
The Bottom Line
Melanotan II occupies a unique position in the grey-market peptide landscape. Its pharmacological effects (tanning, sexual arousal) are among the most reliably produced of any unregulated peptide — users who inject MT-II will almost certainly get darker. The question is whether cosmetic tanning justifies the risk profile of a nonselective melanocortin agonist with documented adverse events including rhabdomyolysis, priapism, and a theoretical (but biologically plausible) melanoma concern.
The pharmaceutical industry’s answer was no — the clinical development of MT-II was abandoned in favor of selective derivatives. Afamelanotide (Scenesse) was developed as an MC1R-selective agonist for a specific medical indication. Bremelanotide (Vyleesi) was developed to isolate the sexual function effects. Neither of these approved drugs carries the same profile of nonselective receptor activation that makes MT-II both effective as a tanning agent and concerning as a safety matter.
If cosmetic tanning is the goal, conventional self-tanners and bronzers achieve the same visual result without systemic melanocortin receptor activation.
Dorr RT et al., Life Sci, 1996;58(20):1777–1784; Wessells H et al., Urology, 2000;56(4):641–646; Habbema L et al., Int J Dermatol, 2017;56(10):975–980; Hjuler KF et al., Dermatology, 2014;228(1):34–36; Van Hout MC & Brennan R, J Subst Use, 2015; WADA 2026 Prohibited List; FDA public safety communications.
This profile will be updated as new research becomes available. Last reviewed: March 2, 2026.